Literature DB >> 8986439

A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.

K R Clark1, F Voulgaropoulou, P R Johnson.   

Abstract

Adeno-associated virus (AAV) vectors are being developed for in vivo and ex vivo gene transfer to human cells. At present, widespread usage of AAV vectors is limited primarily by difficulties in generating recombinant virions on a scale sufficient for in-depth preclinical and clinical trials. However, recent work in several laboratories suggests that this technical obstacle should be overcome in the near future. As a result, it can be anticipated that the interest in AAV vectors will expand, Thus, it becomes important to develop assay systems that will permit accurate quantification of the infectivity of AAV vectors derived from a variety of sources. We have developed an assay using a cell line that expresses AAV helper functions (rep and cap) upon induction by adenovirus infection. This assay system is based on the replication of input rAAV genomes rather than transgene expression (transduction). Thus, infectivity titrations in this system yield an estimation of rAAV infectious particles irrespective of the promoter or transgene present in the vector genome. Moreover, this assay method is more sensitive than conventional methods being used in other laboratories.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986439

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  30 in total

1.  High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids.

Authors:  L Cao; Y Liu; M J During; W Xiao
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes.

Authors:  Marcela P Cataldi; Douglas M McCarty
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

3.  Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.

Authors:  J E Conway; S Zolotukhin; N Muzyczka; G S Hayward; B J Byrne
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy.

Authors:  Mario Mietzsch; Sabrina Grasse; Catherine Zurawski; Stefan Weger; Antonette Bennett; Mavis Agbandje-McKenna; Nicholas Muzyczka; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther       Date:  2014-01-23       Impact factor: 5.695

Review 6.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

7.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 8.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

9.  Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.

Authors:  Anne D Lewis; Ruju Chen; David C Montefiori; Philip R Johnson; K Reed Clark
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.